|
|
|
| Research progress of biomarkers for early identification and prognosis evaluation in sepsis |
| CHEN Shilin1 WANG Lan2 DENG Yaping2 |
1.Department of Pneumology，Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China;
2.Department of Emergency, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China |
|
|
|
Abstract Sepsis is a group of clinical syndromes with high incidence and high mortality. Early recognition and diagnosis is the key to improve its prognosis. Biomarkers can evaluate the physiopathologic mechanism objectively, contribute to diagnose disease, monitor curative effect and predict prognosis. In order to better guide clinical diagnosis and treatment, it is necessary to seek new biomarkers. In recent years, many scholars have done a lot of work on sepsis biomarkers. Most of the researches focus on the molecules expressed on the phagocytic cell membrane, cytokines and acute phase proteins. This paper is to discuss the recent researches on related biomarkers.
|
|
|
|
|
|
[1] Bone RC，Balk RA，Cerra FB，et al. American college of chest physicians/society of critical care medicine consensus conference：definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis [J]. Crit Care Med，1992，20（6）：864-874.
[2] Singer M，Deutschman CS，Seymour CW，et al. The third international consensus definitions for sepsis and septic shock（Sepsis-3）[J]. JAMA，2016，315（8）：801-810.
[3] Angus DC. The lingering consequences of sepsis：a hidden public health disaster？[J]. JAMA，2010，304（16）：1833-1834.
[4] Schuetz P，Aujesky D，Müller C，et al. Biomarker-guided personalised emergency medicine for all-hope for another hype？[J]. Swiss Med Wkly，2015，145：w14079.
[5] Liu Y，Hou JH，Li Q，et al. Biomarkers for diagnosis of sepsis in patients with systemic inflammatory response syndrome：a systematic review and meta-analysis [J]. Springer Plus，2016，5（1）：2091-2100.
[6] Ríos-Toro JJ，Márquez-Coello M，García-álvarez JM，et al. Soluble membrane receptors，interleukin 6，procalcitonin and C reactive protein as prognostic markers in patients with severe sepsis and septic shock [J]. PLoS One，2017，12（4）：e0175254.
[7] Su L，Han B，Liu C，et al. Value of soluble TREM-1，procalcitonin，and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units：a prospective cohort study [J]. BMC Infect Dis，2012，12：157.
[8] 艾波，李文强.脓毒症生物标志物研究进展[J].微循环学杂志，2016，26（4）：71-76.
[9] Rolli J，Loukili N，Levrand S，et al. Bacterial flagellin elicits widespread innate immune defense mechanisms，apoptotic signaling，and a sepsis-like systemic inflammatory response in mice [J]. Crit Care，2010，14（4）：R160.
[10] 罗运山，刘易林，邓霞梅，等.可溶性髓样细胞触发性受体-1清除率评估脓毒症休克患者预后的价值[J].实用医学杂志，2018，34（1）：67-70.
[11] 黄丹.可溶性髓系细胞触发受体-1、降钙素原及超敏C反应蛋白在脓毒血症诊断中的价值[J].内科急危重症杂志，2017，23（1）：32-34，69.
[12] Zou Q，Wen W，Zhang XC. Presepsin as a novel sepsis biomarker [J]. World J Emerq Med，2014，5（1）：16-19.
[13] Shozushima T，Takahashi G，Matsumoto N，et al. Usefulness of presepsin （sCD14-ST）measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome [J]. J lnfect Chemother，2011，17（6）：764-769.
[14] 韦国华，蒋明勇，金腊梅.Presepsin对脓毒症诊断价值的Meta分析[J].中国循证医学杂志，2016，16（3）：286-291.
[15] Fabriek BO，van Bruggen R，Deng DM，et al. The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria [J]. Blood，2009，113（4）：887-892.
[16] Feng L，Zhou X，Su LX，et al. Clinical significance of soluble hemoglobin scavenger receptor cd163（scd163）in sepsis，a prospective study [J]. PLoS One，2012，7（7）：e38400.
[17] Schulte W，Bernhagen J，Bucala R. Cytokines in sepsis：potent immunoregulators and potential therapeutic targets-an updated view [J]. Mediators Inflamm，2013， 2013： 165974.
[18] 胡敏，王继贵.脓毒症相关生物标志物研究进展[J].中华临床实验室管理电子杂志，2016，4（2）：95-98.
[19] Remick DG，Bolgos G，Copeland S，et al. Role of interleukin-6 in mortality from and physiologic response to sepsis [J]. Infect Immun，2005，73（5）：2751-2757.
[20] 杨旭，刘洪羽，陈鹤.固有免疫中信号转导和转录激活因子在脓毒症中的作用[J].国际免疫学杂志，2013，36（5）：379-382.
[21] 李彦，杨建萍，顾承东.细胞因子在脓毒症中的研究进展[J].中日友好医院学报，2014，28（5）：298-301.
[22] 尹承芬，李彤，高心晶，等.降钙素原对成人脓毒症诊断准确性的Meta分析[J].中华危重病急救医学，2015，27（9）：743-749.
[23] 石婷婷，李双庆，梁利波.降钙素原在感染中的应用及研究进展[J].中华全科医学，2018，16（4）：620-625.
[24] 钱素云，刘娟.脓毒症/严重脓毒症/脓毒性休克患儿血清白蛋白水平与预后关系的研究[J].中华儿科杂志，2012，50（3）：184-187.
[25] 宇世飞，李芳秋.降钙素原的临床应用进展[J].医学研究生学报，2016，29（2）：206-209.
[26] Yan L，Liao P，Xu LL，et al. Usefulness of procalcitonin in elderly patients with bacterial infection [J]. Clin Lab，2014，60（1）：139-142.
[27] Meisner M. Update on procalcitonin measurements [J]. Ann Lab Med，2014，34（4）：263-273.
[28] Rhodes A，Evans LE，Alhazzani W，et al. Surviving sepsis campaign：international guidelines for management of sepsis and septic shock：2016 [J]. Intensive Care Med，2017，43（3）：304-377.
[29] Keir I，Dickinson AE. The role of antimicrobials in the treatment of sepsis and critical illness-related bacterial infections：examination of the evidence [J]. J Vet Emerq Crit Care，2015，25（1）：55-62.
[30] Pepys MB，Hirschfield GM. C-reactive protein：a critical update [J]. J Clin Invest，2003，111（12）：1805-1812.
[31] Samsudin I，Vasikaran SD. Clinical utility and measurement of procalcitonin [J]. Clin Biochem Rev，2017，38（2）：59-68. |
|
|
|
